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health states based on visual acuity (VA): >20/40, 20/40 to
>20/80, 20/80 to >20/200, 20/200 to >20/400, and >20/400. The
model incorporates patients across all lesion subtypes: predom-
inately classic, minimally classic, and occult. All drug and pro-
cedure costs were derived from US published sources, including
Medicare Part B Drugs Average Sales Price and RBRVS. Expert
interviews were conducted to determine adverse events treatment
patterns and vision rehabilitation resource use. Relative risks and
costs associated with effects associated with declining VA
(depression, bone fractures, skilled nursing facilities, and nursing
homes) were extracted from a Medicare analysis. Transition
probabilities were derived from published trial data for both
products for each of the 3-month cycles. Utilities were derived
from similar published sources as previous AMD models. Results
are expressed as vision years, quality-adjusted life years
(QALYs), medical costs and other costs, as well as the average
cost per vision year and QALY gained. RESULTS: For a lifetime
analysis the average cost per vision year was $20,459 for
Macugen and $26,079 for Visudyne and the average cost per
QALY was $19,609 for Macugen and $20,136 for PDT. A
patient treated with Macugen had on average 3.68 vision years
over a lifetime compared to 2.65 for a patient treated with Visu-
dyne. CONCLUSIONS: Macugen treatment produces more
years of sight than Visudyne for AMD treated patients. Macugen
is more cost-effective versus active treatment with Visudyne. A
limitation of the model is the absence of direct clinical compar-
ison between the products.
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OBJECTIVES: Many patients suffering from glaucoma ﬁnd it
necessary to use a second adjunctive topical agent to adequately
reduce the intraocular pressure (IOP). New more convenient
ﬁxed combination products containing two active anti-glaucoma
medications have been developed. The objective of this analysis
is to compare the cost of brimonidine/timolol ﬁxed combination
(Combigan®) with concomitant administration of brimonidine
(Alphagan®) and timolol, dorzolamide/timolol ﬁxed combina-
tion (Cosopt®), and concomitant administration of dorzolamide
(Trusopt®) and timolol. METHODS: RCTs have documented
equivalent safety and efﬁcacy in terms of IOP control of combi-
nation products in comparison with their individual components
(Sall et al., 2003; Solish et al., 2004). A cost-minimization analy-
sis including drug costs and visits at the ophthalmologist was
carried out for UK and other European counties with both a
health care and drug alone perspective. An RCT (Simmons et al.,
2001) has shown that Alphagan+timolol was more effective than
Trusopt+timolol in terms of patients achieving target IOP, there-
fore a cost-effectiveness analysis was constructed for this com-
parison. RESULTS: The 3-months health care costs analysis
(drug alone) in the UK using Combigan was £264.00 (£30.00)
compared with £268.11 (£34.11) for Alphagan+timolol and
£264.15 (£30.15) for Cosopt. With a 12-months perspective,
including additional drug and visits, the health care costs (drug
alone) rose to £510.00 (£120.00) for Combigan compared 
with £526.44 (£136.44) for Alphagan+timolol and £510.60
(£120.60) for Cosopt. The cost-effectiveness analysis docu-
mented that Alphagan was more cost-effective than Trusopt
adjunctively. CONCLUSION: Combigan provided better cost
value than Alphagan+timolol adjunctively. The use of Combigan
instead of Alphagan+timolol would result in annual societal
savings of around £728,000 in the UK. Combigan resulted in
slightly lower health care costs when modeling equal effective-
ness compared with Cosopt.
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OBJECTIVE: To compare the cost-effectiveness of early treat-
ment in disease progression of age-related macular degeneration
(AMD) to later treatment. A comprehensive model compares
starting treatment with Macugen (pegaptanib sodium), a new
treatment for AMD indicated for all patients with neovascular
AMD and standard care in patients with early disease progres-
sion (i.e., better visual acuity [VA]) versus late disease progres-
sion (i.e., worse VA). METHODS: A Markov framework was
used to model lifetime movement of an AMD cohort through
health states based on VA: >20/40, 20/40 to >20/80, 20/80 to
>20/200, 20/200 to >20/400, and >20/400. Drug and procedure
costs were derived from US published sources. Expert interviews
were conducted to determine adverse events treatment patterns
and vision rehabilitation resource use. Relative risks and costs
associated with effects associated with declining VA were
extracted from a Medicare analysis. Transition probabilities
were derived from published trial data for both products for each
of the 3-month cycles. Utilities were derived from similar pub-
lished sources as previous AMD models. Results are expressed
as vision years, quality-adjusted life years (QALYs), medical
costs, and other costs, as well as the incremental cost per vision
year and QALY gained. Three runs of the model were conducted
with cohorts of patients starting in one of the following health
states: 20/40 to >20/80; 20/80 to >20/200; and 20/200 to
>20/400. RESULTS: For lifetime analysis incremental cost-
effectiveness ratios (ICERs) per vision year gained were $19,744,
$23,377, and $58,512 and ICERs per QALY gained were
$46,911, $67,058, and $135,400 versus standard care for
patients started in the 20/40 to >20/80, 20/80 to >20/200, and
20/200 to >20/400 states, respectively. CONCLUSIONS: Treat-
ing patients early when presenting with AMD results in lower
ICERs than waiting to treat patients until their VA worsens. To
achieve maximum cost beneﬁts treatment should begin as soon
as possible.
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OBJECTIVE: To estimate the efﬁciency of latanoprost against
the ﬁxed-combination of dorzolamide/timolol in treating
patients with glaucoma in Spain. METHODS: A cost-minimiza-
tion analysis was carried out by building a decision analytical
model, because the effectiveness of both therapeutic options 
in lowering intraocular pressure (IOP) was similar in a per-
formed systematic review of the literature. However, dorzo-
lamide/timolol was associated with a higher incidence of adverse
